Volume Alert - CERS 4.62 Cerus Corp $CERS Hit a high today of 4.65 Closing the day 10:30 at 4.62 +0.43 +10.26% With a day low of 4.29 and a total volume of 1,161,387.
CERS Recent Posts: http://investorshangout.com/Cerus-Corp-CERS-53652/
CERS Cerus Corp Recent Headline News
Cerus Up 8.1%, Shares Break Through Resistance (CERS)
Comtex SmarTrend(R) - 2 hrs 29 mins ago
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 8.1% to $4.53 on 1.3x average daily volume. Cerus has traded 1.5 million shares thus far today, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (7.9% to the Dow's 0.5%) and outperformed the S&P 500 (7.9% to the S&P's 0.3%) during today's trading.
CERS: 4.38 (+0.19)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.38 (+0.19), AGEN: 3.00 (-0.01), NVAX: 5.23 (-0.01), ALXN: 191.49 (-2.20), PPHM: 1.46 (-0.01), THLD: 3.01 (-0.13), GSK: 45.66 (+0.04), OMER: 19.70 (-0.01)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.38 (+0.19), PCYC: 136.56 (-0.81), CLDX: 14.29 (-0.52), INCY: 71.04 (-0.83), BIND: 10.10 (+0.12), CELG: 106.81 (-1.44), OMER: 19.70 (-0.01), VSTM: 9.24 (-0.13), GILD: 104.06 (-2.84), OGXI: 2.13 (-0.05), ANTH: 1.84 (+0.02), NVAX: 5.23 (-0.01)
Technical Updates on Health Care Supplies Sector Stocks - Align Technology, DENTSPLY Intl., Baxano Surgical, Cerus, and Alere
PR Newswire - Wed Nov 05, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Align Technology Inc. (NASDAQ: ALGN), DENTSPLY International Inc. (NASDAQ: XRAY), Baxano Surgical Inc. (NASDAQ: BAXS), Cerus Corporation (NASDAQ: CERS), and Alere Inc. (NYSE: ALR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, November 04, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,383.84, up 0.10% and the NASDAQ Composite closed at 4,623.64, down 0.33%. The S&P 500 finished the session 0.28% lower at 2,012.10. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index gaining 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
CERS: 4.38 (+0.19), BAXS: 0.06 (-0.12), ALGN: 54.72 (-0.14), ALR: 39.97 (-0.13), XRAY: 51.86 (-0.09)
Cerus' (CERS) CEO William Greenman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 6:30PM CST
CERS: 4.38 (+0.19)
Cerus posts 3Q loss
Automated Insights - Tue Nov 04, 5:33PM CST
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $10.8 million in its third quarter.
CERS: 4.38 (+0.19)
Cerus misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:08PM CST
CERS: 4.38 (+0.19)
Cerus Corporation Reports Third Quarter 2014 Results
Business Wire - Tue Nov 04, 3:01PM CST
Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter and nine months ended September 30, 2014.
CERS: 4.38 (+0.19)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.91 (-0.02), ITRI: 41.14 (-0.50), AWAY: 31.25 (+0.45), OKE: 55.65 (-0.81), HR: 25.89 (+0.15), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.61 (-0.02), ADEP: 8.77 (-0.17), CBSO: 31.03 (+0.22), NSTG: 12.40 (+0.24), MITT: 19.10 (-0.08), CRTO: 37.80 (+0.52), FOXA: 34.81 (+0.17), OKS: 48.09 (+0.11), JMBA: 12.74 (+0.02), IVR: 16.23 (+0.01), CSU: 22.93 (-0.07), MYGN: 33.47 (+0.48), JIVE: 6.62 (-0.05), GAS: 51.73 (-0.39), COUP: 15.95 (-0.06), NRP: 12.60 (-0.23), MOSY: 1.77 (+0.10), COHR: 58.27 (-0.61), DOX: 47.52 (-0.18), CKEC: 28.27 (-0.13), OAS: 25.57 (-0.80), PAYC: 23.30 (+0.95), PCYC: 136.56 (-0.81), AXLL: 42.80 (-0.43), NP: 57.52 (-0.42), BIRT: 3.66 (-0.14), ATVI: 20.09 (-0.32), EXAM: 37.61 (-0.08), P: 18.52 (-0.27), JAZZ: 172.18 (-1.35), PBPB: 13.50 (-0.20), EXEL: 1.79 (-0.02), CERS: 4.38 (+0.19), DVN: 62.79 (-1.28), FEYE: 33.26 (+0.11), CHUY: 22.20 (-0.29), FRGI: 56.28 (-0.39), GHDX: 33.24 (+0.25), PACD: 6.57 (-0.30), BIO: 111.36 (-0.57), BIOL: 2.34 (-0.03), JKHY: 60.40 (-0.43), KAR: 33.62 (-0.03), CDXS: 2.26 (-0.14), MPO: 3.00 (-0.19), FANG: 64.50 (-0.31), CORT: 3.04 (-0.02), CALD: 15.68 (+0.04)
Cerus Announces Agreement With Kawasumi Laboratories for the Development of INTERCEPT Platelets Kits in Japan
Business Wire - Wed Oct 29, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that it has entered into a partnership agreement with Kawasumi Laboratories to develop an INTERCEPT platelet kit designed for use in Japan.
CERS: 4.38 (+0.19)
American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks
Business Wire - Thu Oct 23, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) today announced that the American Red Cross will participate in Cerus' clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of chikungunya and dengue virus.
CERS: 4.38 (+0.19)
Cerus reports November 4
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:39AM CDT
CERS: 4.38 (+0.19)
Cerus to Release Third Quarter 2014 Results on November 4, 2014
Business Wire - Wed Oct 22, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Tuesday, November 4, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.38 (+0.19)
Strength Seen in Cerus (CERS): Stock Gains 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:46AM CDT
Cerus (CERS) was a big mover last session, with shares rising over 6% on the day.
CERS: 4.38 (+0.19), ICUI: 83.82 (-0.91), ZLTQ: 26.99 (-0.41), ABAX: 55.01 (+0.81)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 8:21AM CDT
CERS: 4.38 (+0.19), SCOK: 3.21 (-0.01), NCR: 28.12 (-0.61), TKMR: 16.61 (+0.51), VSR: 2.99 (unch), CNL: 53.39 (-0.13), PT: 1.71 (-0.03), CMRX: 32.86 (-1.02), QEP: 23.60 (-0.87), IBM: 161.91 (-0.01), APT: 2.84 (-0.16), PLX: 2.11 (+0.12), NLNK: 31.12 (-1.27), IBIO: 1.11 (unch), LAKE: 11.54 (-0.70), SHOR: 8.12 (-0.07)
Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma
Business Wire - Mon Oct 20, 7:31AM CDT
Cerus Corporation (NASDAQ:CERS) today announced submission of a clinical protocol to the U.S. Food and Drug Administration (FDA) to make the INTERCEPT Blood System for plasma available under a Compassionate Use Investigational Device Exemption (IDE) for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy. A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide a benefit.
CERS: 4.38 (+0.19)
Citigroup and Domino's are big market movers
AP - Tue Oct 14, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
CERS: 4.38 (+0.19), HD: 98.40 (-0.09), ATLS: 36.60 (-0.17), C: 53.04 (-0.38), CSX: 36.57 (-0.20), AWI: 49.30 (+0.17), JNJ: 108.62 (-0.13), ALCS: 0.30 (+0.01), AES: 13.60 (+0.16), JPM: 60.06 (-0.50), GILD: 104.05 (-2.85), AAL: 43.93 (+0.50), DPZ: 91.50 (-0.15), STO: 21.51 (-0.57), OUTR: 63.10 (-0.68)
Traders Get Bullish on Shares of Cerus, Shares Up 8.8% (CERS)
Comtex SmarTrend(R) - Tue Oct 14, 10:07AM CDT
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 8.8% to $4.20 on 1.8x average daily volume. Thus far today, Cerus has traded 1.7 million shares, vs. average volume of 909,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.6%) during today's trading.
CERS: 4.38 (+0.19)
U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks
Business Wire - Tue Oct 07, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Cerus' clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of Chikungunya and dengue virus.
CERS: 4.38 (+0.19)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.38 (+0.19), ECYT: 6.45 (-0.03), GALT: 4.95 (-0.05)
CERS Recent Posts: http://investorshangout.com/Cerus-Corp-CERS-53652/
CERS Cerus Corp Recent Headline News
Cerus Up 8.1%, Shares Break Through Resistance (CERS)
Comtex SmarTrend(R) - 2 hrs 29 mins ago
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 8.1% to $4.53 on 1.3x average daily volume. Cerus has traded 1.5 million shares thus far today, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (7.9% to the Dow's 0.5%) and outperformed the S&P 500 (7.9% to the S&P's 0.3%) during today's trading.
CERS: 4.38 (+0.19)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.38 (+0.19), AGEN: 3.00 (-0.01), NVAX: 5.23 (-0.01), ALXN: 191.49 (-2.20), PPHM: 1.46 (-0.01), THLD: 3.01 (-0.13), GSK: 45.66 (+0.04), OMER: 19.70 (-0.01)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.38 (+0.19), PCYC: 136.56 (-0.81), CLDX: 14.29 (-0.52), INCY: 71.04 (-0.83), BIND: 10.10 (+0.12), CELG: 106.81 (-1.44), OMER: 19.70 (-0.01), VSTM: 9.24 (-0.13), GILD: 104.06 (-2.84), OGXI: 2.13 (-0.05), ANTH: 1.84 (+0.02), NVAX: 5.23 (-0.01)
Technical Updates on Health Care Supplies Sector Stocks - Align Technology, DENTSPLY Intl., Baxano Surgical, Cerus, and Alere
PR Newswire - Wed Nov 05, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Align Technology Inc. (NASDAQ: ALGN), DENTSPLY International Inc. (NASDAQ: XRAY), Baxano Surgical Inc. (NASDAQ: BAXS), Cerus Corporation (NASDAQ: CERS), and Alere Inc. (NYSE: ALR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, November 04, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,383.84, up 0.10% and the NASDAQ Composite closed at 4,623.64, down 0.33%. The S&P 500 finished the session 0.28% lower at 2,012.10. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index gaining 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
CERS: 4.38 (+0.19), BAXS: 0.06 (-0.12), ALGN: 54.72 (-0.14), ALR: 39.97 (-0.13), XRAY: 51.86 (-0.09)
Cerus' (CERS) CEO William Greenman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 6:30PM CST
CERS: 4.38 (+0.19)
Cerus posts 3Q loss
Automated Insights - Tue Nov 04, 5:33PM CST
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $10.8 million in its third quarter.
CERS: 4.38 (+0.19)
Cerus misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:08PM CST
CERS: 4.38 (+0.19)
Cerus Corporation Reports Third Quarter 2014 Results
Business Wire - Tue Nov 04, 3:01PM CST
Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter and nine months ended September 30, 2014.
CERS: 4.38 (+0.19)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.91 (-0.02), ITRI: 41.14 (-0.50), AWAY: 31.25 (+0.45), OKE: 55.65 (-0.81), HR: 25.89 (+0.15), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.61 (-0.02), ADEP: 8.77 (-0.17), CBSO: 31.03 (+0.22), NSTG: 12.40 (+0.24), MITT: 19.10 (-0.08), CRTO: 37.80 (+0.52), FOXA: 34.81 (+0.17), OKS: 48.09 (+0.11), JMBA: 12.74 (+0.02), IVR: 16.23 (+0.01), CSU: 22.93 (-0.07), MYGN: 33.47 (+0.48), JIVE: 6.62 (-0.05), GAS: 51.73 (-0.39), COUP: 15.95 (-0.06), NRP: 12.60 (-0.23), MOSY: 1.77 (+0.10), COHR: 58.27 (-0.61), DOX: 47.52 (-0.18), CKEC: 28.27 (-0.13), OAS: 25.57 (-0.80), PAYC: 23.30 (+0.95), PCYC: 136.56 (-0.81), AXLL: 42.80 (-0.43), NP: 57.52 (-0.42), BIRT: 3.66 (-0.14), ATVI: 20.09 (-0.32), EXAM: 37.61 (-0.08), P: 18.52 (-0.27), JAZZ: 172.18 (-1.35), PBPB: 13.50 (-0.20), EXEL: 1.79 (-0.02), CERS: 4.38 (+0.19), DVN: 62.79 (-1.28), FEYE: 33.26 (+0.11), CHUY: 22.20 (-0.29), FRGI: 56.28 (-0.39), GHDX: 33.24 (+0.25), PACD: 6.57 (-0.30), BIO: 111.36 (-0.57), BIOL: 2.34 (-0.03), JKHY: 60.40 (-0.43), KAR: 33.62 (-0.03), CDXS: 2.26 (-0.14), MPO: 3.00 (-0.19), FANG: 64.50 (-0.31), CORT: 3.04 (-0.02), CALD: 15.68 (+0.04)
Cerus Announces Agreement With Kawasumi Laboratories for the Development of INTERCEPT Platelets Kits in Japan
Business Wire - Wed Oct 29, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that it has entered into a partnership agreement with Kawasumi Laboratories to develop an INTERCEPT platelet kit designed for use in Japan.
CERS: 4.38 (+0.19)
American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks
Business Wire - Thu Oct 23, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) today announced that the American Red Cross will participate in Cerus' clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of chikungunya and dengue virus.
CERS: 4.38 (+0.19)
Cerus reports November 4
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:39AM CDT
CERS: 4.38 (+0.19)
Cerus to Release Third Quarter 2014 Results on November 4, 2014
Business Wire - Wed Oct 22, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Tuesday, November 4, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.38 (+0.19)
Strength Seen in Cerus (CERS): Stock Gains 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:46AM CDT
Cerus (CERS) was a big mover last session, with shares rising over 6% on the day.
CERS: 4.38 (+0.19), ICUI: 83.82 (-0.91), ZLTQ: 26.99 (-0.41), ABAX: 55.01 (+0.81)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 8:21AM CDT
CERS: 4.38 (+0.19), SCOK: 3.21 (-0.01), NCR: 28.12 (-0.61), TKMR: 16.61 (+0.51), VSR: 2.99 (unch), CNL: 53.39 (-0.13), PT: 1.71 (-0.03), CMRX: 32.86 (-1.02), QEP: 23.60 (-0.87), IBM: 161.91 (-0.01), APT: 2.84 (-0.16), PLX: 2.11 (+0.12), NLNK: 31.12 (-1.27), IBIO: 1.11 (unch), LAKE: 11.54 (-0.70), SHOR: 8.12 (-0.07)
Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma
Business Wire - Mon Oct 20, 7:31AM CDT
Cerus Corporation (NASDAQ:CERS) today announced submission of a clinical protocol to the U.S. Food and Drug Administration (FDA) to make the INTERCEPT Blood System for plasma available under a Compassionate Use Investigational Device Exemption (IDE) for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy. A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide a benefit.
CERS: 4.38 (+0.19)
Citigroup and Domino's are big market movers
AP - Tue Oct 14, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
CERS: 4.38 (+0.19), HD: 98.40 (-0.09), ATLS: 36.60 (-0.17), C: 53.04 (-0.38), CSX: 36.57 (-0.20), AWI: 49.30 (+0.17), JNJ: 108.62 (-0.13), ALCS: 0.30 (+0.01), AES: 13.60 (+0.16), JPM: 60.06 (-0.50), GILD: 104.05 (-2.85), AAL: 43.93 (+0.50), DPZ: 91.50 (-0.15), STO: 21.51 (-0.57), OUTR: 63.10 (-0.68)
Traders Get Bullish on Shares of Cerus, Shares Up 8.8% (CERS)
Comtex SmarTrend(R) - Tue Oct 14, 10:07AM CDT
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 8.8% to $4.20 on 1.8x average daily volume. Thus far today, Cerus has traded 1.7 million shares, vs. average volume of 909,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.6%) during today's trading.
CERS: 4.38 (+0.19)
U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks
Business Wire - Tue Oct 07, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Cerus' clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of Chikungunya and dengue virus.
CERS: 4.38 (+0.19)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.38 (+0.19), ECYT: 6.45 (-0.03), GALT: 4.95 (-0.05)
